Brought to you by 
BioAlliance and TopoTarget merge
10 Sep 2020
Executive Summary
Publicly held cancer companies TopoTarget AS and BioAlliance Pharma SA entered into a merger agreement that will culminate with TopoTarget operating as a wholly owned BioAlliance subsidiary, owning approximately 1/3 of the combined entity’s stock. For every 27 shares held, TopoTarget stockholders get two BioAlliance shares. Based on the pre-announcement market average, the deal is worth €83.4mm ($115mm).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BioAlliance and TopoTarget merge
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice